Previous studies showed that SLC12A7 copy gains may serve as a putative molecular indicator of malignancy in indeterminate adrenal tumors, including a marker of malfunctioning tumors [25, 26]. This evidence concerns the gene SLC12A7 and adrenal gland neoplasm.